Related references
Note: Only part of the references are listed.BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS
Simona Soverini et al.
LEUKEMIA (2021)
Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
Simona Soverini et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Christopher A. Eide et al.
CANCER CELL (2019)
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T3151+ clones in TKI-resistant CML
Mathias Schneeweiss-Gleixner et al.
EBIOMEDICINE (2019)
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
Konstantin Byrgazov et al.
HAEMATOLOGICA (2018)
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
Konstantin Byrgazov et al.
HAEMATOLOGICA (2018)
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Matthew S. Zabriskie et al.
CANCER CELL (2014)
Share Paper
